

## Special Issue

# Medical Imaging in Brain Tumor: Charting the Future

### Message from the Guest Editors

This Special Issue, entitled “Medical Imaging in Brain Tumor: Charting the Future”, welcomes publications of cutting-edge research in advanced imaging technologies in the diagnosis, treatment planning, and monitoring of brain tumors. After rapid advancements in imaging modalities such as MRI, CT, PET and emerging techniques like AI-driven image analysis, this issue highlights innovative research and breakthroughs that are reshaping the field. We invite submissions that focus on improving tumor detection, classification, and segmentation, as well as enhancing the understanding of tumor biology through imaging biomarkers. This issue will address the integration of imaging data with radiomics, radiogenomics, and personalized medicine, offering new avenues for precision oncology. By bringing together multidisciplinary perspectives, this Special Issue seeks to provide a comprehensive overview of current advancements and future directions in brain tumor imaging, ultimately contributing to improved patient outcomes and clinical decision-making.

### Guest Editors

Dr. Subrata Bhattacharjee

1. Medical Research Institute, Pusan National University, Yangsan 50612, Republic of Korea
2. Department of Biomedical Engineering, School of Medicine, Pusan National University, Yangsan 50612, Republic of Korea

Dr. Mansoor Hayat

Section of Neurosurgery, Department of Surgery, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada

### Deadline for manuscript submissions

30 September 2025



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/232184](https://mdpi.com/si/232184)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).